Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered offering of 16,778,524 shares of its ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Immix Biopharma (IMMX) stock jumps as the company posts mid-stage trial results for its lead asset NXC-201 in AL amyloidosis, ...
Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) –– CR rate now 95% (19 of 20 patients) –– ...
Shares of Immix Biopharma rose after the company reported positive updated data for a Phase 2 trial of a bone marrow disease treatment and said it would sell $150 million worth of stock in an ...
Immix Biopharma Inc. IMMX stock fell Thursday after the company reported a 95% complete response rate in its clinical trial ...
Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds An ...
LOS ANGELES, CA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL ...
LAS VEGAS — Immix, a provider of software for commercial monitoring centers, and Robotic Assistance Devices (RAD), a subsidiary of Artificial Intelligence Technology Solutions (AITX), have announced ...
LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that ...
Financing includes leading U.S. biotechnology institutional investors and mutual funds –LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results